Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.74 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.74 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.74 |
| ▸ | PPARG | P37231 | 7/20 | 0.74 |
| ▸ | PPARD | Q03181 | 7/20 | 0.74 |
| ▸ | PPARA | Q07869 | 7/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 4/20 | 0.74 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | TLR2 | O60603 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | FABP4 | P15090 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.74 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16023553 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL516197 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL2354538 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL16131158 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL13069503 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL23128413 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL1358545 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL10448425 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL19076153 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL14213379 | 1.00 | FFAR4 (0.74) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738204-B2 | Printing process for preparing controlled scattering effects | XEROX CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190322881-A1 | Printing Process For Preparing Controlled Scattering Effects | XEROX CORPORATION | 2019-10-24 | — | — | US | disclosed |
| US-9980898-B2 | Polymer composition for high-heat application comprising thermo-releasable substance | DSM IP ASSETS B.V. (NL) | 2018-05-29 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2108683-B1 | CURABLE OVERCOAT COMPOSITIONS | XEROX CORP (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-9096767-B2 | Curable solid inks containing cyclohexyl-based crystalline gellants | XEROX CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096767-B2 | Curable solid inks containing cyclohexyl-based crystalline gellants | XEROX CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-20070123642-A1 | Phase change inks containing curable isocyanate-derived compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123642-A1 | Phase change inks containing curable isocyanate-derived compounds | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20060128903-A1 | Process for the controlled increase in the molecular weight of polyethylenes | ROTH MICHAEL | 2006-06-15 | — | — | US | disclosed |
| EP-1282630-B1 | Process for Reducing the Molecular Weight of Polypropylene Using Hydroxylamine Esters | CIBA SC HOLDING AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| EP-1655303-A2 | Hydroxylamine esters as polimerization initiators | Ciba SC Holding AG (CH) | 2006-05-10 | — | — | EP | disclosed |
| US-7030196-B2 | Process for reducing the molecular weight of polypropylene | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| US-20030216494-A1 | Hydroxylamine esters as polymerization initiators | CIBA SPECIALTY CHEMICALS CORP. | 2003-11-20 | — | — | US | disclosed |
| EP-1282630-A1 | HYDROXYLAMINE ESTERS AS POLYMERIZATION INITIATORS | Ciba SC Holding AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001090113-A1 | HYDROXYLAMINE ESTERS AS POLYMERIZATION INITIATORS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2001-11-29 | — | — | WO | disclosed |
| EP-0963753-A2 | Utilisation of C20-40 dialkyldimerate for increasing the light protection factor and/or the UV-A protection of cosmetic or dermatologic light protection agents | Beiersdorf Aktiengesellschaft (DE) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216494-A1 | Hydroxylamine esters as polymerization initiators | PNMT, HPGDS, HAAO | FFAR4 328/4885FFAR1 407/4885GPR84 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.